FDA issues safety alert over SGLT2-inhibitors
There have been 12 cases of life-threatening necrotising fasciitis in patients with type 2 diabetes
Clare Pain
5th September 2018
The TGA is looking into a safety issue concerning SGLT-2 inhibitors after the US Food and Drug Administration (FDA) warned a rare genital gangrene has been reported in patients with type 2 diabetes taking the medications.
Login to see the rest of this article
Log In
Your Australian Doctor Group network login gives you access to Australian Doctor, Medical Observer, How To Treat, 6minutes, and Pharmacy News
Not a member?
Join Medical Observer
0 Comments